Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease

Malignant melanoma

Age

67 years

Gender

male

Ethnicity

Caucasian

Derivation

This is one of a very extensive series of melanoma lines (see also ATCC HTB-70, ATCC HTB-72 and ATCC HTB-73) isolated by T. Takahashi and associates.

Clinical Data

67 years

Caucasian

male

Antigen Expression

Blood Type O; Rh+; HLA A1, A2, B12, B14, Cw5

Tumorigenic

Yes

Effects

Yes, forms malignant melanoma

Complete Growth Medium

The base medium for this cell line is Eagle's Minimum Essential Medium (EMEM; ATCC 30-2003). To make the complete growth medium, add the following components to the base medium: fetal bovine serum (FBS; ATCC 30-2020) 15%.

Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the cells subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with the Office of Technology Development, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Contact email: otd@mskcc.org